The impact of disease burden on the outcome of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (SCT) has not been well defined. Data from several retrospective series suggest that overt leukemia at the time of transplant increases the risk of relapse. We reviewed the outcomes of 68 consecutive adults with AML (n ¼ 60) or myelodysplastic syndromes (MDS) (n ¼ 8) who received an allogeneic SCT at the University of Chicago between May 1986 and October 2002 to confirm the importance of currently recognized risk factors for overall survival (OS) and progression-free survival (PFS). In addition, we wanted to determine whether quantification of residual disease by blast percentage or cytogenetic abnormalities at the time of SCT was correlated with outcome. AML subtypes based on the FAB classification were as follows:
The impact of disease burden on the outcome of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (SCT) has not been well defined. Data from several retrospective series suggest that overt leukemia at the time of transplant increases the risk of relapse. We reviewed the outcomes of 68 consecutive adults with AML (n ¼ 60) or myelodysplastic syndromes (MDS) (n ¼ 8) who received an allogeneic SCT at the University of Chicago between May 1986 and October 2002 to confirm the importance of currently recognized risk factors for overall survival (OS) and progression-free survival (PFS). In addition, we wanted to determine whether quantification of residual disease by blast percentage or cytogenetic abnormalities at the time of SCT was correlated with outcome. AML subtypes based on the FAB classification were as follows: M0 ¼ 9, M1 ¼ 9, M2 ¼ 16, M3 ¼ 2, M4 ¼ 16, M5 ¼ 3, M6 ¼ 5. Cytogenetic analysis was available from 52 patients. Using standard morphologic criteria, 34 patients were in complete remission (CR) and 34 had visible leukemia present. The majority of donors were HLA-identical siblings (n ¼ 55). In all, 56 patients received myeloablative conditioning regimens and 12 received a reduced-intensity, fludarabine-based conditioning regimen. OS and PFS times were 7.1 months (95% CI, 4.8-10.4) and 5.1 months (95% CI, 3.2-7.8), respectively. Median follow-up from SCT was 4.6 years (range, 0.6-17.0) for survivors. In multivariate analysis, the following factors were found to be associated with worse survival: (1) increased percentage of blasts in the bone marrow at the time of SCT, (2) presence of acute graft-versus-host disease, (3) mismatched donor, (4) Zubrod performance score of X2, and (5) age X45 years. We also found a trend towards improved outcome among patients in cytogenetic remission as compared to those who had residual cytogenetic abnormalities and those in overt relapse. These data support an association between pre-transplant disease burden and poor outcome after SCT. Approximately 60-80% of patients less than 60 years old with acute myeloid leukemia (AML) achieve complete remission (CR) with standard induction chemotherapy regimens. 1 Unfortunately, the majority of these patients eventually suffer a relapse, and long-term overall survival rates are approximately 30%. Allogeneic stem cell transplantation (SCT) has been proven to be an effective approach for post-remission consolidation, improving long-term leukemia-free survival (LFS) rates to 45-70% for patients who undergo transplantation in first complete remission (CR1). 2 In contrast, AML patients who undergo transplantation with more advanced disease or in relapse achieve LFS rates of 30% at best. [2] [3] [4] [5] [6] [7] The goal of this single institution, retrospective study was to review the clinical characteristics of consecutive AML and myelodysplastic syndrome (MDS) patients receiving allogeneic SCT at the University of Chicago between 1986 and 2002, and to investigate the potential predictors of progression-free survival (PFS) and overall survival (OS). Currently recognized risk factors associated with worse outcome include disease status at the time of SCT, older age, and the development of graft-versus-host disease (GVHD). 8 For patients transplanted in CR1, cytogenetic pattern is also a significant predictor of outcome. [4] [5] [6] [7] [9] [10] [11] [12] We were interested in evaluating these factors, as well as determining whether quantification of residual disease at the time of transplant was correlated with outcome. We were particularly interested in evaluating whether the percentage of residual bone marrow blasts, and/or detection of residual disease by cytogenetic analysis, affected the outcome after SCT. 12 Cytogenetic abnormalities that were not classified into one of the above prognostic categories were labeled as unclassifiable (n ¼ 11). The disease status of patients at the time of transplant was determined using standard morphologic criteria. CR was defined as a normocellular bone marrow biopsy with o5% blasts (with no Auer rods or leukemic phenotype), neutrophils 41000/ml, platelet count 4100 000/ml, and transfusion independence.
Patients and methods

Patients
All patients were treated at the University of Chicago on prospective protocols using institutional transplant guidelines for antimicrobial, antifungal, and antiviral prophylaxis. Transfusion support was given to maintain hemoglobin concentrations greater than 8.0 g/dl and platelet counts greater than 10 000/ml. Informed consent was obtained from all patients and donors.
The diagnosis of GVHD was confirmed by biopsy in some cases, but was ultimately determined by clinical presentation. Acute GVHD was clinically graded as 0-IV based on standard published criteria; 13 chronic GVHD was classified as none, limited, or extensive. 14 
Statistical methods
Data were analyzed in June 2003. OS was calculated from the date of SCT to the time of death, or was censored at the date of last follow-up. PFS was calculated from the date of SCT to the time of relapse, progression, or death, whichever came first. Surviving patients were censored at the last follow-up in remission. Relapse was defined as recurrence of leukemia at any site. Transplant-related mortality (TRM) was defined as any death occurring in a patient without progression or relapse of leukemia. GVHD occurring within the first 100 days of transplant was considered acute, whereas that occurring after day 100 was defined as chronic.
OS and PFS were calculated using the method of Kaplan and Meier. 15 Pre-transplant clinical characteristics and presence of GVHD were evaluated in univariate Cox regression models, 16 and those with P-values p0.15 were included in multivariate models. A final multivariate model was chosen using a backward elimination process. Clinical factors evaluated in the OS and PFS analyses were age at time of SCT (continuous and X45 years old vs o45 years old), disease subtype, cytogenetic risk group, disease status at time of SCT, performance status (X2 vs o2), preparative regimen (myeloablative vs reduced intensity), degree of HLA matching (mismatched vs HLA-identical), source of stem cells, gender, presence of dysplasia, and percentage of blasts measured in the bone marrow immediately prior to SCT. To detect the possible influences of GVHD on outcome, patients were categorized into those with or without acute and chronic GVHD. The presence of acute and chronic GVHD was analyzed as time-varying covariates for both OS and PFS. Disease burden was also evaluated at the cytogenetic level. The median OS and PFS times for patients who were in a complete morphologic and cytogenetic remission at time of SCT were compared to those who were in complete morphologic remission but had residual cytogenetic abnormalities detected, and to those who had visible leukemia observed at time of SCT. Patients with a normal, diploid karyotype were excluded from the first two groups for this analysis ( Table 1 ). All analyses were carried out using Stata, Version 8 (Stata Corp., College Station, TX, USA).
Results
Patient and treatment characteristics
Patient and treatment characteristics are summarized in Table 1 . In all, 19 patients were transplanted in CR1. The remaining patients received salvage chemotherapy, and at the time of transplant, 15 were in second CR, 10 in first relapse, three in second relapse, seven in refractory relapse, and seven had primary refractory disease. Seven patients had untreated disease. The majority of patients had a performance score of 0 or 1 (n ¼ 61); seven had a score of 2 or 3. The majority of patients received myeloablative conditioning regimens based on total body irradiation (TBI) (n ¼ 18) or busulfan (n ¼ 38). In total, 12 patients received fludarabine and high-dose melphalan-based conditioning and in vivo T-cell depletion with alemtuzumab. 17 The source of stem cells was bone marrow (BM) for 25 patients and peripheral blood (PB) for 43 patients. The majority of transplants were sibling transplants, with 55 HLA-identical donors and 10 mismatched related donors. Two patients had a matched unrelated donor, and one patient had a mismatched unrelated donor. GVHD prophylaxis included tacrolimus or cyclosporine in all patients, and methotrexate in all except those who had received alemtuzumab during conditioning.
Survival, PFS, TRM, and GVHD
The median OS and PFS times were 7.1 months (95% CI, 4.8-10.4) and 5.1 months (95% CI, 3.2-7.8), respectively, after a median follow-up of 4.6 years (range, 0.6-17.0) for patients surviving as of their last follow-up (Figures 1 and  2 ). In all, 22 patients remain alive and disease free, with a 10-year PFS probability of 0.28 (95% CI, 0.18-0.39).
Out of 68 patients, 46 have died. In total, 30 died from the following transplant-related complications: four from hemorrhage, 12 from sepsis, five from GVHD, and nine from major organ dysfunction. In addition, 16 patients died after relapse of leukemia ( Table 2 ). The overall incidence of acute GVHD was 49% (n ¼ 33), with 22% (n ¼ 15) developing grade III-IV GVHD. The overall incidence of chronic GVHD was 41% (n ¼ 19) of those who survived beyond day 100, with 17% (n ¼ 8) developing extensive chronic GVHD. GVHD ¼ graft-versus-host disease.
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Prognostic factor analysis
Clinical factors significant in univariate models for OS were age at the time of SCT, disease type (MDS vs AML), performance status, HLA matching, percentage of blasts present in the BM immediately prior to the SCT, and the development of acute or chronic GVHD. In univariate models for PFS, the significant clinical factors were age at time of SCT, disease status at time of SCT using standard morphologic criteria, Zubrod performance score, HLA matching, percentage of blasts present in the BM immediately prior to SCT, and the presence of acute or chronic GVHD. Clinical variables significant in both the OS and PFS final multivariate models were the occurrence of acute GVHD, age, Zubrod performance score, HLA match, and percentage of blasts in the BM at time of SCT ( In an additional exploratory analysis, patients were stratified into three groups based on status of disease at the time of SCT as assessed by morphologic and cytogenetic criteria. Both median OS and PFS times were longer for patients who were in cytogenetic remission at time of SCT compared to those who only had a morphologic remission or had overt leukemia (Tables 4 and 5 ). OS and PFS times were similar for patients with residual cytogenetic abnormalities and those with morphologic relapse. However, the estimates of the median OS and PFS times for these groups have a high degree of imprecision due to the small sample sizes (see confidence intervals in Tables 4 and 5) . Nevertheless, our data suggest that morphologic assessment of CR is not as sensitive as cytogenetic analysis to predict outcome following SCT.
Discussion
The impact of disease burden on long-term outcome after allogeneic transplantation has been investigated by many single center and cooperative studies, usually by comparing the outcome of patients transplanted in CR with that of patients transplanted in relapse. [18] [19] [20] For example, data from the IBMTR on 3503 transplants performed for AML between 1989 and 1995 showed that the 3-year probability of relapse was 2472% for patients transplanted in first remission, compared to 4578% for those transplanted in second or subsequent remission, and 5775% for patients transplanted in relapse. The 3-year probabilities of LFS were 5972, 3575, and 2674%, respectively. 21 Sierra et al evaluated the significance of disease burden in 161 AML receiving bone marrow transplants from unrelated donors between 1985 and 1998. Similar to results from related transplants, LFS at 5 years was 50712% for patients transplanted in first remission, compared to 27717% for patients transplanted in second or subsequent remission, and 773% for patients transplanted in relapse. 3 Among patients transplanted in relapse, those with o30% leukemic blasts in the marrow and no circulating blasts had a 37% incidence of relapse after BMT, those with X30% leukemic blasts in the marrow and no circulating blasts had an incidence of 44%, and those with marrow and circulating leukemic blasts had an incidence of 50%.
In patients with MDS, there is also a correlation between the percentage of blasts in the bone marrow and the outcome of transplantion. Pre-transplant variables were evaluated in 59 MDS patients receiving a matched related bone marrow transplant. Patients with fewer blasts at the time of transplant had a decreased rate of relapse compared to those with excess blasts. 22 As these studies illustrate, there is a correlation between disease burden and risk of relapse post transplant. This information is critical in the difficult decision-making process of how to advise patients with regard to proceeding with transplant when they have residual disease present prior to transplant. Our retrospective analysis was another attempt to address this issue. The level of disease burden was quantitated in an effort to correlate disease outcome with the pre-transplant leukemic burden. We were able to detect an association between the percentage of blasts in the marrow and survival after transplant. Owing to the retrospective nature of our analysis and the limited patient sample, our data should be considered preliminary, and need to be confirmed in larger patient populations. CI ¼ confidence interval.
Impact of disease burden on outcome of allogeneic stem cell transplant P Kebriaei et al However, our findings corroborate those from other series described above. Taken together, these data suggest that further cytoreductive therapy may be necessary prior to transplant in patients with high levels of circulating leukemic blasts, in an effort to decrease the relapse rate, despite potential added toxicity from additional chemotherapy. 23 A prospective, randomized trial investigating the feasibility of allogeneic SCT in aplasia after induction therapy in adults with high-risk AML is currently in progress. Thus far, 107 AML patients have been enrolled on this multicenter study, with no treatment-associated deaths reported. 24 In an effort to further quantify the disease burden, the impact of an abnormal karyotype at the time of transplant was examined in patients in morphologic CR. Patients in cytogenetic and morphologic remission had longer median survival and PFS times when compared to patients who still had detectable cytogenetic abnormalities or those in relapse. This difference was not statistically significant, perhaps due to the small number of patients in each group, but suggests a better disease outcome with further disease reduction prior to SCT. Quantifying disease burden at the molecular level is becoming standard procedure for certain subsets of AML. Minimal residual disease (MRD) quantified by flow cytometry during remission and post-remission chemotherapy has been found to be a strong predictor for relapse in some AML patients. 25 Furthermore, it has been noted to be a strong predictor for relapse for AML patients undergoing autologous SCT. 26 The added benefit of a graftversus-leukemia effect on disease burden needs to be evaluated. Therefore, MRD should be further studied pre-and post-allogeneic stem cell transplant. It may have significant prognostic and therapeutic implications for post-transplant management in this setting.
Our analysis also confirmed the importance of age on outcome after transplant. 8, 27, 28 In the multivariate analysis for OS, age X45 years correlated with decreased survival. The risk of death increased by a factor of 1.57 (57%) per decade. The negative impact of older age on treatment outcome was corroborated by our colleagues at the University of Chicago. Clinical predictors of TRM were evaluated in another series of patients who received a reduced intensity transplant regimen for high-risk or refractory hematologic malignancies at the University of Chicago between 2002 and 2004. Again, patient age and performance status were noted to be significant predictors for TRM in a multivariate analysis. 29 We were not able to assess the contribution of other prognostic factors on outcome due to the retrospective nature of this analysis. However, it is likely that age is a surrogate for other factors relating to patient fitness. In an attempt to further clarify these factors, Sorror et al have described a modified Charlson Comorbidity Index, and suggest using this index prior to transplant to assess individual patient TRM and OS. 30 Finally, we were unable to confirm an association between cytogenetic risk group and PFS or OS due to the limited sample size.
In conclusion, age and level of disease burden at time of transplant were found to be significant prognostic variables in multivariate analyses for survival in this study. We established a correlation between the percentage of blasts and outcome after transplant, and also a relationship between cytogenetic remission and a favorable outcome. These results obviously require confirmation in larger prospective studies but, if confirmed, may provide further rationale for strategies of aggressive induction therapy prior to allogeneic transplantation. 23 Minimal disease burden pre-transplant combined with a graft-versus-leukemia effect following transplant may result in improved overall survival in this patient population.
